RNAC Q3 2018 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$215M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$16M

Net Income

-$16M

EPS (Diluted)

$-21.43

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$60M

Total Liabilities

$50M

Stockholders' Equity

$10M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$27,000	-100.0%
Gross Profit	$0	$27,000	-100.0%
Operating Income	-$16M	-$14M	-15.1%
Net Income	-$16M	-$15M	-9.0%